Literature DB >> 4049462

Carbamazepine protein binding and disposition in pregnancy.

M S Yerby, P N Friel, D Q Miller.   

Abstract

The pregnancies of five women with epilepsy treated with carbamazepine monotherapy were studied prospectively. Free and total serum concentrations of carbamazepine and its epoxide and dihydrodiol metabolites were analyzed at monthly intervals from the first trimester through 8 weeks postpartum. Assays were by high performance liquid chromatography, and free compounds were separated by ultrafiltration. The mean intrinsic clearance of carbamazepine (clearance of free drug corrected for changes in maternal body weight) did not change appreciably during pregnancy and the postpartum period. The mean free fractions of carbamazepine and the epoxide were elevated during pregnancy (0.25 and 0.50) compared with postpartum (0.22 and 0.43). Mean total maternal carbamazepine and epoxide concentrations were 40 and 48% higher than neonatal levels at birth, but maternal and neonatal free concentrations agreed closely. The ratio of epoxide to parent drug increased during pregnancy, as reported by other authors. Evidence is presented that this may be a result of inhibition of further biotransformation of the epoxide rather than of increased production. Two patients missed at least one dose of carbamazepine during labor, resulting in markedly reduced serum concentrations at delivery.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4049462     DOI: 10.1097/00007691-198507030-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  13 in total

Review 1.  Therapeutic drug monitoring in pregnancy: rationale and current status.

Authors:  C Knott; F Reynolds
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 2.  Pharmacokinetic changes during pregnancy and their clinical relevance.

Authors:  R Loebstein; A Lalkin; G Koren
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

3.  Carbamazepine clearance and seizure stability during pregnancy.

Authors:  Emily L Johnson; Zachary N Stowe; James C Ritchie; D Jeffrey Newport; Melanee L Newman; Bettina Knight; Page B Pennell
Journal:  Epilepsy Behav       Date:  2014-03-13       Impact factor: 2.937

Review 4.  Epilepsy in women of childbearing age.

Authors:  M Saunders
Journal:  BMJ       Date:  1989-09-02

Review 5.  The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state.

Authors:  M D Hill; F P Abramson
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

Review 6.  Treatment of epilepsy in pregnancy.

Authors:  I Nulman; D Laslo; G Koren
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 7.  Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium.

Authors:  Torbjörn Tomson; Dina Battino
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 9.  Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest?

Authors:  Page B Pennell
Journal:  Epilepsia       Date:  2008-12       Impact factor: 5.864

Review 10.  Management of epilepsy during pregnancy.

Authors:  Dina Battino; Torbjörn Tomson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.